Michelle C. Werner agonized over whether the gene therapy treatment Elevidys was right for her teenage son. But to him, the ...

A possible gene therapy approval and a series of major trials readouts set the stage for a busy year of drug development in Duchenne muscular dystrophy.

We hypothesize that Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder co-occur with a greater than random frequency. In this study, we set out to reject the ...

After escaping a clinical hold several years back, Dyne Therapeutics has revealed new phase 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251. The readout notes several serious ...

Pfizer is “evaluating appropriate next steps” for its Duchenne muscular dystrophy (DMD) gene therapy after it failed a phase 3 trial. Fordadistrogene movaparvovec (PF-06939926) was unable to ...

Hudson Sanford is a seven-year-old boy that was diagnosed with Duchenne muscular dystrophy (DMD) when he was four years old.

WASHINGTON, Aug. 27, 2024 /PRNewswire/ -- Marking a significant milestone in improving the lives of children affected by Duchenne muscular dystrophy (Duchenne), Parent Project Muscular Dystrophy ...

KUWAIT CITY, Sept 11: Assistant Undersecretary for Medical Support Services at the Ministry of Health, Dr. Abdullah Al-Fars, announced on Wednesday that Kuwait is the first country in the Middle East ...

Patients treated with 20 mg/kg of DYNE-251 Q4W had a mean absolute dystrophin expression of 3.71% of normal. Dyne is initiating registrational cohorts in the DELIVER trial and plans to provide an ...

KUWAIT, Sept 11: Dr. Laila Bastaki, Head of the Genetic Diseases Center at the Ministry of Health, emphasized the importance of incorporating genetic testing for Duchenne muscular dystrophy (DMD) into ...

The second elephant calf in two weeks has been born at a California zoo. African elephant Amahle gave birth early Monday morning, according to the Fresno Chaffee Zoo. The event came 10 days after ...

On Tuesday, Dyne Therapeutics Inc. (NASDAQ:DYN) announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to exon ...